Cervical Cancer: Symptoms, Diagnosis, Staging, and Treatment

Cervical cancer develops when normal epithelial cells lining the cervix—the narrow neck of the uterus connecting the upper womb to the vagina—undergo genetic alterations that cause them to multiply uncontrollably. The cervix contains two main anatomical zones: the ectocervix, which is lined by protective squamous cells, and the endocervical canal, lined by glandular, mucus-producing cells. The junction where these two tissues meet is called the transformation zone. This dynamic biological area is where cellular turnover is highest and where the vast majority of pre-cancerous abnormalities and malignant tumours originate.

Under normal conditions, healthy cervical cells mature, shed, and are systematically replaced in an orderly fashion. However, when the genetic control mechanisms within these cells become disrupted—predominantly by the sustained activity of viral oncoproteins—the cells can progress through stages of cervical intraepithelial neoplasia (CIN). CIN represents pre-invasive dysplastic changes graded from 1 to 3. If CIN 3 is left unmonitored and untreated over a span of several years or decades, these abnormal cells can break through the protective basement membrane of the epithelium, invading the underlying cervical stroma and establishing invasive cervical cancer.

Once invasive, the malignancy has the capacity to extend locally into surrounding structures such as the vaginal walls, the supportive pelvic connective tissues (parametria), the bladder, and the rectum. Malignant cells may also enter the lymphatic channels or bloodstream, potentially spreading to regional pelvic and para-aortic lymph nodes or distant organs such as the lungs, liver, or bones. Because this cellular progression is typically gradual, timely intervention can disrupt the cycle well before invasive spread occurs.

If you or a loved one has recently received an abnormal smear result or a confirmed diagnosis of cervical cancer, it is essential to pause and take a steady breath. Hearing the word 'cancer' or receiving a call back from a screening clinic naturally triggers deep distress. In plain terms, an abnormal screening test usually means that cellular changes have been spotted very early, often long before cancer has formed, giving your clinicians an opportunity to remove or observe those cells safely.

If invasive cancer has already been diagnosed, it means your care will immediately be directed to a dedicated multidisciplinary team—comprising gynaecological oncologists, radiation oncologists, medical oncologists, clinical nurse specialists, and radiologists. Your team will not rush into a one-size-fits-all plan. Instead, they will carry out precise examinations and scans to determine the exact stage and biological features of the tumour. This information forms the roadmap for a treatment plan designed to offer the highest chance of cure while preserving your bodily function, future fertility where appropriate, and long-term well-being.

In its earliest, most curable stages, cervical cancer is frequently asymptomatic. Pre-cancerous changes and microscopic invasive lesions rarely produce noticeable physical sensations or pain, which is precisely why routine screening tests are vital even when an individual feels entirely healthy. When symptoms do emerge, they are most commonly related to alterations in vaginal bleeding patterns caused by fragile, newly formed blood vessels on the surface of the tumour.

The most frequent clinical symptom is abnormal vaginal bleeding. This includes post-coital bleeding (bleeding after sexual intercourse), intermenstrual bleeding (bleeding occurring between regular monthly periods), or any vaginal bleeding that occurs after the menopause. Some patients notice an unusual or persistent vaginal discharge, which may be watery, pink, pale brown, or foul-smelling. Discomfort or pain during sexual intercourse (dyspareunia) can also occur as the cervix becomes inflamed or structurally altered by tumour tissue.

As disease advances locally within the pelvis, additional symptoms may develop. These include persistent dull or sharp pain in the lower back, pelvis, or lower abdomen, which may radiate down one or both legs due to pressure on pelvic nerve pathways. Advanced tumours pressing on adjacent organs can cause urinary symptoms, such as difficulty passing urine, haematuria (blood in the urine), or swelling in one or both legs (lymphoedema) caused by obstructed lymphatic drainage. Any unexplained, persistent bleeding or pelvic pain warrants prompt medical evaluation by a GP or gynaecologist.

The fundamental biological cause of nearly all cervical cancers is persistent infection with high-risk strains of the human papillomavirus (HPV). HPV is an extremely common, sexually transmitted DNA virus that infects the epithelial surfaces of the skin and mucous membranes. More than 100 strains of HPV exist, but only roughly 14 are classified as high-risk oncogenic types. Among these, HPV type 16 and HPV type 18 are responsible for roughly 70% of all invasive cervical cancer cases worldwide, with types 31, 33, 45, 52, and 58 accounting for a substantial portion of the remainder.

Infection with HPV is exceptionally common; the vast majority of sexually active adults will contract at least one strain of the virus at some point in their lives. In roughly 90% of individuals, the immune system naturally clears or suppresses the viral infection within one to two years without causing symptoms or long-term harm. However, in a small proportion of people, the host immune response fails to eliminate the high-risk virus, leading to chronic, persistent infection. Over years, viral DNA can integrate into the host cell's genome, driving the continuous production of two potent viral oncoproteins designated E6 and E7.

These oncoproteins disrupt the natural tumour-suppressor networks within cervical epithelial cells. Specifically, E6 binds to and degrades the p53 tumour-suppressor protein, which normally triggers cellular repair or programmed cell death (apoptosis) when DNA damage occurs. Simultaneously, E7 inactivates the retinoblastoma protein (pRb), releasing control over the cell cycle and driving uncontrolled cellular proliferation. Without these cellular gatekeepers, genetic errors accumulate unchecked, eventually transforming benign, infected cells into pre-cancerous lesions and, ultimately, invasive carcinoma.

While persistent high-risk HPV infection is the indispensable initiator of cervical cancer, it is rarely sufficient on its own to cause malignant transformation; secondary co-factors influence whether a persistent infection progresses to invasive disease. One of the most significant modifiable risk factors is tobacco smoking. Chemical carcinogens from cigarette smoke are absorbed into the bloodstream and concentrated in cervical mucus. These toxins damage cervical DNA directly while simultaneously dampening local immune defences, impairing the body's capacity to clear HPV infections and doubling the risk of high-grade lesions.

Another critical factor is state of the immune system. Individuals living with human immunodeficiency virus (HIV) or those receiving long-term immunosuppressive therapies (such as organ transplant recipients) have substantially higher rates of persistent HPV infection and experience more rapid progression from pre-cancer to invasive disease. Other co-factors include prolonged use of oral contraceptive pills (for more than five to ten years, though the risk decreases after stopping), high parity (having given birth to multiple children), early age at first sexual intercourse, and co-infection with other sexually transmitted organisms like Chlamydia trachomatis, which may induce chronic local inflammation.

Primary prevention revolves around disrupting this pathway through vaccination and routine screening. Modern prophylactic HPV vaccines, such as the nonavalent vaccine, protect against high-risk types 16, 18, 31, 33, 45, 52, and 58, as well as low-risk types 6 and 11 (which cause genital warts). Vaccination is ideally administered before sexual debut, between the ages of 9 and 14, although catch-up vaccination remains beneficial for older adolescents and young adults. Coupled with smoking cessation and routine participation in national screening programmes, the vast majority of cervical cancers are entirely preventable.

The diagnostic journey typically begins in one of two ways: either following an abnormal routine screening test or after an individual presents to a clinician with symptoms such as unexplained vaginal bleeding. In modern screening programmes, cervical samples obtained via a gentle brush are first tested for the molecular presence of high-risk HPV. If high-risk HPV is detected, liquid-based cytology is performed on the same sample to examine the cells under a microscope for signs of dyskaryosis or dysplasia. If high-risk HPV is accompanied by abnormal cytology, or if HPV persists on repeat testing, the patient is referred for a specialised examination called colposcopy.

A colposcopy is an outpatient procedure performed by a gynaecologist. Using a specialised binocular microscope with a bright light (the colposcope), which remains outside the body, the clinician closely examines the illuminated cervix. Dilute solutions of acetic acid (vinegar) and Lugol's iodine are applied to the cervix; these agents temporarily alter the light-reflecting properties of abnormal cells, making areas of dysplasia turn white (acetowhite changes) or fail to take up iodine stain. If suspicious areas are identified on the transformation zone, the clinician performs targeted cervical punch biopsies to collect tiny tissue samples for histological analysis.

If the transformation zone extends deeply into the endocervical canal where it cannot be fully visualised, or if a punch biopsy reveals high-grade disease or early invasion, an excisional procedure is performed. This may be a Large Loop Excision of the Transformation Zone (LLETZ), also referred to as a Loop Electrosurgical Excision Procedure (LEEP), or a cold-knife cone biopsy. These excisions serve both a diagnostic and therapeutic purpose, providing an intact piece of tissue to evaluate the depth of invasion, tumour margins, and presence of lymphovascular space invasion (LVSI). A definitive histological diagnosis by an expert pathologist is essential before any definitive cancer management begins.

Once invasive cervical cancer is histologically confirmed, the next crucial step is staging, which determines how far the tumour has grown into the cervix and whether it has spread to adjacent tissues or distant sites. Cervical cancer is staged according to the International Federation of Gynecology and Obstetrics (FIGO) system. In 2018, the FIGO system was updated to integrate modern cross-sectional imaging modalities—such as pelvic Magnetic Resonance Imaging (MRI) and Positron Emission Tomography-Computed Tomography (PET-CT)—as well as pathological findings, replacing the historical reliance purely on basic clinical examination.

The FIGO staging framework spans four main stages. Stage I is strictly confined to the cervix uteri. It is subdivided into Stage IA (microscopic lesions measuring less than 5 mm in depth) and Stage IB (clinically visible lesions or microscopic lesions measuring 5 mm or more in depth, further stratified by size into IB1, IB2, and IB3). Stage II indicates that the tumour has extended beyond the uterus into the upper two-thirds of the vagina (Stage IIA) or into the parametria (the supportive connective tissue adjacent to the cervix), but has not reached the pelvic sidewall (Stage IIB).

Stage III represents more extensive regional disease. Stage IIIA involves the lower third of the vagina, while Stage IIIB has grown into the pelvic sidewall or causes obstruction of the ureters leading to hydronephrosis (kidney swelling) or a non-functioning kidney. Notably, the 2018 update introduced Stage IIIC, which designates lymph node involvement irrespective of local tumour dimensions: Stage IIIC1 indicates pelvic lymph node metastases, and Stage IIIC2 indicates spread to the para-aortic lymph nodes. Finally, Stage IV reflects advanced spread; Stage IVA signifies direct extension into the mucosal lining of the bladder or rectum, while Stage IVB denotes distant metastases to distant organs such as the lungs, liver, or distant skeletal bones.

Beyond basic histological confirmation of cancer type (such as squamous cell carcinoma or adenocarcinoma), modern oncology relies heavily on molecular and biomarker testing. When a biopsy specimen is evaluated, the pathologist examines tissue architecture and performs immunohistochemical staining to identify specific proteins that can influence prognosis and dictate therapy. One fundamental assessment is evaluating lymphovascular space invasion (LVSI). The presence of cancer cells within microscopic capillary or lymphatic vessels indicates a higher propensity for regional lymph node spread and guides the extent of required lymphadenectomy or adjuvant therapies.

In recurrent, persistent, or metastatic cervical cancer, molecular biomarker testing is standard clinical practice. The most critical biomarker currently evaluated is Programmed Death-Ligand 1 (PD-L1) expression. Pathologists assess PD-L1 using a metric known as the Combined Positive Score (CPS), which quantifies the number of PD-L1-staining cells (including tumour cells, lymphocytes, and macrophages) relative to the total number of viable tumour cells. A CPS of 1 or greater indicates PD-L1 positivity, which qualifies patients for treatment with immune checkpoint inhibitors such as pembrolizumab in combination with systemic chemotherapy.

Additional molecular profiling is increasingly performed to uncover rare but therapeutically actionable alterations. Testing for Mismatch Repair deficiency (dMMR) or Microsatellite Instability-High (MSI-H) status can identify tumours with defective DNA repair pathways, which are exceptionally sensitive to immunotherapeutic agents. Similarly, assessing tumour mutational burden (TMB) and screening for specific gene fusions, such as neurotrophic tyrosine receptor kinase (NTRK) fusions, or alterations in HER2 (ERBB2), may unlock precision targeted therapies or novel clinical trial opportunities for patients who have exhausted standard lines of treatment.

Cervical cancer is categorised by the specific cell type from which the malignancy originates. The vast majority—accounting for roughly 75% to 80% of all cases—are squamous cell carcinomas. These tumours arise from the flat, thin, skin-like squamous epithelial cells that cover the ectocervix. Squamous cell carcinomas are strongly linked to HPV types 16 and 18 and are typically detected readily through standard cervical screening cytology, as they usually begin along the visible outer transformation zone of the cervix.

The second most frequent subtype is cervical adenocarcinoma, which accounts for roughly 20% to 25% of cases. Adenocarcinomas develop from the glandular, mucus-secreting cells that line the interior endocervical canal. Because these tumours originate deeper within the canal, they can be more challenging to sample with routine smear brushes and may grow unnoticed until they reach a larger size. Less common variants include adenosquamous carcinomas (mixed tumours containing both glandular and squamous malignant features) and rare, aggressive neuroendocrine cervical carcinomas, which require distinctive, intensive multimodal systemic chemotherapy regimens closely mirroring small-cell lung cancer protocols.

Treatment for cervical cancer is tailored to the individual patient, guided by the FIGO stage, the tumour's histological subtype, histological risk features, and the patient's personal preferences regarding future fertility. For very early-stage microscopic disease (Stage IA1 without LVSI), a conservative surgical excision, such as a cold-knife cone biopsy with clear margins, is often entirely curative. For patients with early-stage disease (Stage IA2 to select Stage IB1 tumours measuring less than 2 cm) who strongly desire to preserve childbearing potential, a fertility-sparing radical trachelectomy can be performed. In this operation, the cervix and adjacent parametrial tissue are removed, along with a pelvic lymph node assessment, while the body of the uterus (uterine corpus) and ovaries are preserved, allowing for future pregnancy via caesarean delivery.

For early-stage disease where fertility preservation is not required or feasible (Stage IB1, IB2, and select IIA1 tumours), standard management involves a radical hysterectomy accompanied by bilateral pelvic lymphadenectomy or sentinel lymph node mapping. In a radical hysterectomy, the surgeon removes the entire uterus, cervix, upper portion of the vagina, and parametria. The ovaries can frequently be preserved in pre-menopausal women with squamous cell carcinoma, avoiding the sudden onset of surgical menopause. Following surgery, the excised tissues are scrutinised; if intermediate or high-risk features (such as positive surgical margins, nodal involvement, or parametrial spread) are discovered, postoperative adjuvant radiotherapy or chemoradiotherapy is recommended to reduce recurrence risk.

For locally advanced cervical cancer (typically Stages IB3, IIA2, IIB, III, and IVA), definitive concurrent chemoradiotherapy is the international standard of care. This approach combines external beam radiotherapy (EBRT) directed at the pelvis and involved nodal basins with weekly radiosensitising chemotherapy, most commonly intravenous cisplatin. EBRT is followed immediately by image-guided adaptive brachytherapy (IGABT). Brachytherapy is a sophisticated technique wherein sealed radioactive sources are temporarily placed directly inside or adjacent to the tumour via specialized applicators. This delivers an exceptionally high, curative dose of radiation to the cervical tumour mass while rapidly falling off to spare nearby healthy organs, such as the bladder and bowel.

For Stage IVB distant metastatic disease, or persistent and recurrent cancer not amenable to curative local treatments, management centres on systemic therapy. First-line systemic treatment typically comprises a platinum-based chemotherapy doublet (cisplatin or carboplatin with paclitaxel) combined with bevacizumab (an anti-angiogenic monoclonal antibody targeting VEGF) and pembrolizumab (an immune checkpoint inhibitor targeting the PD-1/PD-L1 pathway) for tumours expressing PD-L1 (CPS ≥ 1). For patients who experience disease progression following initial platinum therapy, second-line immunotherapy with agents such as cemiplimab, or antibody-drug conjugates like tisotumab vedotin, provide meaningful treatment avenues.

Participation in well-designed clinical trials represents an essential option throughout the therapeutic continuum. Clinical trials evaluate cutting-edge approaches, including novel antibody-drug conjugates, therapeutic HPV vaccines, bispecific antibodies, and adoptive T-cell therapies. Enrolling in a clinical trial gives patients access to emerging therapeutic agents while contributing to the scientific knowledge that will shape future standards of care. Patients are strongly encouraged to discuss open trials with their oncologists at every major decision point.

Survival statistics for cervical cancer are framed around population-level data gathered across broad cohorts, typically reported as five-year relative survival rates. For early-stage disease confined strictly to the cervix (Stage I), modern multi-modality care yields excellent long-term outcomes, with five-year relative survival rates frequently falling between roughly 80% and 95%, depending on specific tumour size and nodal status. When cancer has spread regionally to adjacent tissues or regional pelvic lymph nodes (Stages II and III), five-year survival rates generally range between roughly 50% and 70% with standard concurrent chemoradiotherapy and image-guided brachytherapy.

In cases where the cancer has spread to distant organs at diagnosis (Stage IVB) or recurs distantly, five-year survival historically dropped below 20%. However, these historical figures reflect data gathered prior to the standard integration of modern immunotherapies, targeted biologics, and refined local salvage therapies. While survival statistics provide helpful broad benchmarks, they cannot predict any individual patient's outcome. An individual's prognosis is shaped by numerous unique variables, including biological subtype, molecular markers, overall health, renal function, performance status, and treatment tolerability. Your gynaecological oncology team is best positioned to provide nuanced perspective on what your specific staging and response to therapy mean for your future.